Although there was a low incidence of ischemic vascular complications, those who had them showed higher rates of all-cause ...

Transcatheter deep venous arterialization was tied to high rates of limb salvage and wound healing in patients with “no ...

Researchers explored the cellular cross-talk between endothelial cells and macrophages contributing to peripheral vascular ...

Cagent Vascular announced the publication of data demonstrating the safety and efficacy of the company’s Serranator percuta ...

REVA Medical, LLC today announced primary endpoint results from the MOTIV BTK randomized pivotal clinical trial evaluating ...

New data from the PROMISE III trial show the LimFlow transcatheter deep venous arterialization system achieved over 80% amputation-free survival at six months in 'no-option' chronic limb-threatening ...

Type 2 diabetes can turn immune cells that help with tissue repair and anti-inflammatory responses into triggers of chronic ...

In 2021, there were 11.96 million new stroke cases worldwide, with ischemic stroke (IS) accounting for 65.3%. China has an ...

Reva Medical, LLC announced primary endpoint results from the pivotal MOTIV BTK randomized clinical trial evaluating the safety a ...

Data from the PROMISE III trial suggest that chronic limb-threatening ischemia (CLTI) patients with no other treatment ...

MOTIV BTK randomized trial met primary efficacy endpoint, with early and sustained clinical benefit in a complex patient populationSAN DIEGO, April 21, 2026 /PRNewswire/ -- REVA Medical, LLC ...

A new study suggests that a novel anti-clotting drug may reduce the risk of a second stroke without increasing bleeding, ...